-+ 0.00%
-+ 0.00%
-+ 0.00%

Liminatus Pharma issues new warrants for 20,688,000 shares in inducement deal

PUBT·06/03/2026 12:34:04
Listen to the news
Liminatus Pharma issues new warrants for 20,688,000 shares in inducement deal
  • Liminatus Pharma entered a warrant exercise agreement covering 10,344,000 shares, cutting the exercise price to USD 0.18.
  • Cash exercise expected to generate USD 1.9 million in gross proceeds before fees and expenses.
  • Issuing new unregistered warrants for 20,688,000 shares at USD 0.18, exercisable only after required Nasdaq stockholder approval.
  • New warrants set to expire five years after stockholder approval.
  • Company plans to file an SEC registration statement for resale of shares issuable upon exercise of the new warrants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030830PRIMZONEFULLFEED9731261) on June 03, 2026, and is solely responsible for the information contained therein.